Theravance, Inc.

Infinity Pharmaceuticals, Inc.

Theravance Biopharma R&d Ip, LLC

Twelve Therapeutics, Inc.

Daniel G Genov

Paul Ross Fatheree

Adam Aaron Goldblum

S Derek Turner

Daniel D Long

Daniel Marquess

Louis Grenier

Seok-Ki Choi

Andre Lescarbeau

Robert S Chao

Praveen Sharma

Brian C Austad

Brian H White

Jyanwei Liu

Junning Lee

Susana Del Rio Gancedo

Alexander Redvers Eberlin

Andrew Hague

Ludovic Sylvain Marc Renou

Solid forms of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphic forms, cocrystals, and amorphous forms thereof, and pharmaceutical compositions thereof.

Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same

Provided herein is a process for the transfer-hydrogenation of ketone analogs of members of the jervine type ofalkaloids, such as cyclopamine. Also provided herein are novel ruthenium transfer-hydrogenation catalysts.

Transfer hydrogenation of cyclopamine analogs

Solid forms of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein. Also provided herein are processes for preparing compounds, solid forms thereof, and pharmaceutical compositions thereof.

Salts and solid forms of isoquinolinones and composition comprising and methods of using the same

The invention provides a crystalline hydrochloride salt of 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with 5-HTreceptor activity, and processes useful for preparing such crystalline salt forms.

Crystalline form of a quinolinone-carboxamide compound

The invention provides novel quinolinone-carboxamide 5-HTreceptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HTreceptor activity, and processes and intermediates useful for preparing such compounds.

[object Object]

The invention provides novel quinolinone-carboxamide 5-HT4 receptor agonist compounds of Formula (I). The invention also provides pharmaceutical compositions comprising such compounds, the use such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds. Wherein; Ris hydrogen, halo, hydroxy, Calkyl, or Calkoxy; Ris Calkyl, or Ccycloalkyl; Ris hydrogen or Calkyl: Ris S(O)Ror C(O)R; Ris hydrogen, Calkyl, Calkyl substituted with &#x2014;OH or Calkoxy, or &#x2014;CH-pyrydyl; Ris Calkyl; or Rand Rtaken together from Calkylenyl; and Ris hydrogen, Calkyl, or pyrydyl; or pharmaceutically-acceptable salt or solvate or stereoisomer thereof. 

Growing community of inventors

Boston, MA, United States of America

Daniel G Genov